Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

ngs derived from Anadys' completed strategic restructuring.

Operating expenses were $9.7 million for the third quarter of 2008, compared to $10.0 million for the third quarter of 2007. Included as a component of Anadys' operating expenses were non-cash, share-based expenses of $0.7 million and $1.4 million for the third quarter of 2008 and 2007, respectively.

The net loss was $9.3 million for the third quarter of 2008, compared to net income of $12.3 million for the third quarter of 2007. Basic and diluted net loss per common share was $0.32 in the third quarter of 2008, compared to net income per common share of $0.43 in the third quarter of 2007. Non-cash share-based expense resulted in a $0.03 increase in basic and diluted net loss per share for the third quarter of 2008 compared to a $0.05 decrease in basic and diluted net income per share for the third quarter 2007.

During the nine months ended September 30, 2008 the Company had no revenue, compared to $23.9 million for the same period in 2007. The revenue recognized in the first nine months of 2007 was primarily derived from the amortization of an upfront payment and a milestone payment under a prior collaboration and the recognition of the previously deferred revenue upon termination of the collaboration. Operating expenses during the nine months ended September 30, 2008 were $25.2 million compared to $28.1 million for the nine months ended September 30, 2007. The decrease in operating expenses was a result of cost savings derived from Anadys' completed restructuring partially offset by increases in development costs for ANA598 and ANA773. For the nine months ended September 30, 2008, Anadys reported a net loss of $23.9 million, compared to $1.4 million for the same period last year. Basic and diluted net loss per common share was $0.83 for the nine months ended September 30, 2008, compared to $0.05 for the same period in 2007.

Recent Development Program Highlights

-- Phase
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... NEW PROVIDENCE, N.J. , Sept. 2, 2014 /PRNewswire/ ... sponsor for MassBio,s 20th Annual Golf Classic, a major ... The event will be held on September 5 at ... Massachusetts . The MassBioEd Foundation ... through educational programs, workforce development, and lifelong ...
(Date:9/2/2014)... a billionth of a meter in size, are around ... benefit human health, as in some innovative early cancer ... viruses, air pollution, traffic emissions, cosmetics, sunscreen and electronics. ... St. Louis, led by Lan Yang, PhD, the Das ... Engineering, and their collaborators at Tsinghua University in China ...
(Date:9/2/2014)... including University of Oregon chemist Geraldine Richmond, have ... self-assembling, synthetic proteins called peptoid nanosheets that mimic ... -- detailed this week in a paper placed ... of the National Academy of Sciences -- ... the two-dimensional peptoid nanosheets that can be used ...
(Date:9/2/2014)... NEW YORK , September 2, 2014 ... Market Study on Membrane Technology in Pharmaceutical, Biopharma and ... Witness Highest Growth by 2019" the global membrane technology market for ... 7,029.9 million in 2014 and is expected to grow ... to reach an estimated value of USD 10,886.0 million ...
Breaking Biology Technology:Linde helps fund STEM education in Massachusetts 2Linde helps fund STEM education in Massachusetts 3Engineers develop new sensor to detect tiny individual nanoparticles 2Engineers develop new sensor to detect tiny individual nanoparticles 3UO-Berkeley Lab unveil new nano-sized synthetic scaffolding technique 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 3Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 4Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 5
... ... ... var shortURL ... we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; } for ...
... ... ... var shortURL = ""; BitlyCB.alertResponse ... grab the first one. for (var r in data.results) { first_result = data.results[r]; break; } for (var key in ...
... in a row, a pair of Rensselaer students took ... held by the American Society of Mechanical Engineers (ASME). ... Jaron Kuppers won top honors in the national competition ... process. The SET process offers a new method for ...
Cached Biology Technology:YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387 2YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387 3YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387 4YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387 5YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387 6YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387 7YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387 8YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387 9Medivir: R&D Day 2Medivir: R&D Day 3Medivir: R&D Day 4Medivir: R&D Day 5Medivir: R&D Day 6Medivir: R&D Day 7Medivir: R&D Day 8Rensselaer mechanical engineers win first place at ASME student manufacturing design competition 2Rensselaer mechanical engineers win first place at ASME student manufacturing design competition 3Rensselaer mechanical engineers win first place at ASME student manufacturing design competition 4
(Date:9/2/2014)... Cancer Center researchers may have discovered a new way ... vulnerable by deficient DNA repair. , The findings were ... , The study, led by James E. Hansen, ... of Medicine, found that cancer cells with deficient DNA ... genetic damage) were significantly more vulnerable to attack by ...
(Date:9/2/2014)... FL, September 2, 2014 In a new study ... from the Florida campus of The Scripps Research Institute ... cells into unique manufacturing sites for molecules that can ... a cell as a reaction vessel and a disease-causing ... a diseased cell," said TSRI Professor Matthew Disney.,"Because the ...
(Date:9/2/2014)... sequence their genetic information. How is it possible ... parts of the body are so different? While every ... additional regulatory layer exists that determines which of the ... modifications of genome-bound histone proteins or the DNA itself ... top of the genetic information and is thus called ...
Breaking Biology News(10 mins):Sabotage as therapy: Aiming lupus antibodies at vulnerable cancer cells 2Scripps Florida scientists make diseased cells synthesize their own drug 2Throwing a loop to silence gene expression 2
... assessment of malnutrition, created by researchers at Penn State, ... diagnosis and treatment. Up to 50 percent of ... be malnourished, according to Gordon Jensen, professor and head ... confusion exists in the clinical community on how to ...
... seeking to refine and improve lung-cancer screening by combining a ... more effectively. The trial combines a CT chest scan and ... to build on recent research demonstrating that CT screening alone ... CT screening of high-risk patients can reduce lung-cancer deaths. But ...
... heel within our cells that bacteria are able to exploit ... their findings could lead to the development of new anti-infective ... resistance. University of Manchester researchers studied Listeria ... listeriosis in humans when digested and found they are ...
Cached Biology News:Researchers unveil new assessment for diagnosing malnutrition 2Trial seeks improved lung-cancer screening by combining imaging and biomarkers 2
Kit for testing the ability of a compound to simulate lipolysis in cultured human adipocytes. Kit contains controls, buffers and reagents for detecting glycerol and non-esterified free fatty acids. A...
... The Experion Pro260 analysis kit for 10 ... to perform protein analysis with the Experion ... Pro260 microfluidic chips, 3 x 520 microliters ... microliters Pro260 ladder (10-260 kD), 400 microliters ...
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
... Staccato Mini-Workstations provide fast and reliable ... proteomics and drug development laboratories. Staccato ... instrumentation to automate basic liquid handling ... are controlled with either Caliper's time ...
Biology Products: